- Conditions
- Bipolar I Disorder
- Interventions
- Bifeprunox
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 3,445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
- Interventions
- Imvotamab
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Cachexia
- Interventions
- GSK2849466, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP015K
- Interventions
- ASP015K, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Miami, Florida • Saint Paul, Minnesota
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- PF-06252616, Placebo
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 15 Years · Male only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 14 more
- Conditions
- Solid Tumor
- Interventions
- KD033 (SAR445710)
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Tampa, Florida • Buffalo, New York + 2 more
- Conditions
- Atherosclerosis
- Interventions
- Selnoflast, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Hepatitis C Virus
- Interventions
- PF-04878691 3mg, PF-04878691 6mg, PF-04878691 9mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-04603629, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- ELA026
- Drug
- Lead sponsor
- Electra Therapeutics Inc.
- Industry
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Solid Tumor
- Interventions
- PEGPH20
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Nashville, Tennessee
- Conditions
- Cystic Fibrosis
- Interventions
- Ethambutol, Rifampin, Azithromycin, Pancrelipase
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 16 Years to 45 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- PF-03446962, Best Supportive Care, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Failure, Chronic
- Interventions
- Obinutuzumab, Intravenous Immunoglobulin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 4 more
- Conditions
- Parkinson's Disease, Levodopa
- Interventions
- Erythromycin, placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Interventions
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Biological
- Lead sponsor
- T-MAXIMUM Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
- Interventions
- AG-120
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
- Interventions
- PD 0332991
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Embryo Transfer
- Interventions
- Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Hyperlipidemia
- Interventions
- 1-MNA, Placebo
- Drug
- Lead sponsor
- Pharmena North America
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- JTZ-951, Placebo
- Drug
- Lead sponsor
- Shionogi Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- MT-0169
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more